PDCD1 and metastatic melanoma: Furthermore, metabolomics analysis has recently identified significant differences in 83 gut metabolites at baseline in responders to anti-PD-1 and anti-CTLA-4 therapy compared to nonresponders with metastatic melanoma [25].